Thinking about cognition: concepts, targets and therapeutics:
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Amsterdam
IOS Press
2006
|
| Schriftenreihe: | Solvay Pharmaceuticals Conferences
v. 5 |
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | International conference proceedings 100 Years after the discovery of Alzheimer's disease, neurological diseases and psychiatric disorders represent the largest and fastest growing unmet medical market with 2 billion affected people worldwide. Life expectancy of humans continues to increase, and the world population is aging. Advanced age may lead to deterioration of cognitive functions of the brain. There seems to be consensus that on the background of aging, several factors may render humans prone to dementia. Psychiatric and neurological isorders such as schizophrenia, bipolar disorder or Parkinson's disease may contribute to development of dementia. More people today are looking for help regarding their learning and memory capabilities. Although increasing knowledge on neuronal networks s transforming our view of the human brain and its function and we understand psychiatric and neurological diseases better today than ever before, novel therapies are needed to respond to the growing demand of patients for assistance with memory loss and earning impairment. In fact, it is expected that novel therapies aiming at the processing of amyloid, or at activation of glutamatergic or nicotinergic systems will demonstrate adequate efficacy in improving learning and memory disturbances. This publication stands as a comprehensive overview of the cellular and molecular mechanisms underlying the development of cognitive impairment. It integrates discoveries concerning dementia, such as mild cognitive impairment and Alzheimer's disease associated dementia vascular dementia, retardation syndromes, and psychiatric and neurological disorders related cognitive impairments. This book will be useful to physicians, biologists, and those pursuing an interest or concerned with memory impairment. 100 Years after te discovery of Alzheimer's disease, neurological diseases and psychiatric disorders represent the largest and fastest growing unmet medical market with 2 billion affected people worldwide. Life expectancy of humans continues to increase, and the world poplation is aging. Advanced age may lead to deterioration of cognitive functions of the brain. There seems to be consensus that on the background of aging, several factors may render humans prone to dementia. Psychiatric and neurological disorders such as shizophrenia, bipolar disorder or Parkinson's disease may contribute to development of dementia. More people today are looking for help regarding their learning and memory capabilities. Although increasing knowledge on neuronal networks is transforming ourview of the human brain and its function and we understand psychiatric and neurological diseases better today than ever before, novel therapies are needed to respond to the growing demand of patients for assistance with memory loss and learning impairment In fact, it is expected that novel therapies aiming at the processing of amyloid, or at activation of glutamatergic or nicotinergic systems will demonstrate adequate efficacy in improving learning and memory disturbances. This publication stands as a comrehensive overview of the cellular and molecular mechanisms underlying the development of cognitive impairment. It integrates discoveries concerning dementia, such as mild cognitive impairment and Alzheimer's disease associated dementia, vascular dementia retardation syndromes, and psychiatric and neurological disorders related cognitive impairments. This book will be useful to physicians, biologists, and those pursuing an interest or concerned with memory impairment |
| Beschreibung: | 1 Online-Ressource (144 p.) |
| ISBN: | 1280810556 1429467711 9781280810558 9781429467711 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV043101231 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151126s2006 |||| o||u| ||||||eng d | ||
| 020 | |a 1280810556 |9 1-280-81055-6 | ||
| 020 | |a 1429467711 |c electronic bk. |9 1-4294-6771-1 | ||
| 020 | |a 9781280810558 |9 978-1-280-81055-8 | ||
| 020 | |a 9781429467711 |c electronic bk. |9 978-1-4294-6771-1 | ||
| 035 | |a (ZDB-4-EBA)ocn124095086 | ||
| 035 | |a (OCoLC)124095086 | ||
| 035 | |a (DE-599)BVBBV043101231 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 153 |2 22 | |
| 245 | 1 | 0 | |a Thinking about cognition: concepts, targets and therapeutics |c C.G. Kruse ... [et al.] (eds.) |
| 264 | 1 | |a Amsterdam |b IOS Press |c 2006 | |
| 300 | |a 1 Online-Ressource (144 p.) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Solvay Pharmaceuticals Conferences |v v. 5 | |
| 500 | |a International conference proceedings | ||
| 500 | |a 100 Years after the discovery of Alzheimer's disease, neurological diseases and psychiatric disorders represent the largest and fastest growing unmet medical market with 2 billion affected people worldwide. Life expectancy of humans continues to increase, and the world population is aging. Advanced age may lead to deterioration of cognitive functions of the brain. There seems to be consensus that on the background of aging, several factors may render humans prone to dementia. Psychiatric and neurological isorders such as schizophrenia, bipolar disorder or Parkinson's disease may contribute to development of dementia. More people today are looking for help regarding their learning and memory capabilities. | ||
| 500 | |a Although increasing knowledge on neuronal networks s transforming our view of the human brain and its function and we understand psychiatric and neurological diseases better today than ever before, novel therapies are needed to respond to the growing demand of patients for assistance with memory loss and earning impairment. In fact, it is expected that novel therapies aiming at the processing of amyloid, or at activation of glutamatergic or nicotinergic systems will demonstrate adequate efficacy in improving learning and memory disturbances. This publication stands as a comprehensive overview of the cellular and molecular mechanisms underlying the development of cognitive impairment. It integrates discoveries concerning dementia, such as mild cognitive impairment and Alzheimer's disease associated dementia vascular dementia, retardation syndromes, and psychiatric and neurological disorders related cognitive impairments. | ||
| 500 | |a This book will be useful to physicians, biologists, and those pursuing an interest or concerned with memory impairment. 100 Years after te discovery of Alzheimer's disease, neurological diseases and psychiatric disorders represent the largest and fastest growing unmet medical market with 2 billion affected people worldwide. Life expectancy of humans continues to increase, and the world poplation is aging. Advanced age may lead to deterioration of cognitive functions of the brain. There seems to be consensus that on the background of aging, several factors may render humans prone to dementia. Psychiatric and neurological disorders such as shizophrenia, bipolar disorder or Parkinson's disease may contribute to development of dementia. More people today are looking for help regarding their learning and memory capabilities. | ||
| 500 | |a Although increasing knowledge on neuronal networks is transforming ourview of the human brain and its function and we understand psychiatric and neurological diseases better today than ever before, novel therapies are needed to respond to the growing demand of patients for assistance with memory loss and learning impairment In fact, it is expected that novel therapies aiming at the processing of amyloid, or at activation of glutamatergic or nicotinergic systems will demonstrate adequate efficacy in improving learning and memory disturbances. This publication stands as a comrehensive overview of the cellular and molecular mechanisms underlying the development of cognitive impairment. It integrates discoveries concerning dementia, such as mild cognitive impairment and Alzheimer's disease associated dementia, vascular dementia retardation syndromes, and psychiatric and neurological disorders related cognitive impairments. | ||
| 500 | |a This book will be useful to physicians, biologists, and those pursuing an interest or concerned with memory impairment | ||
| 650 | 7 | |a SCIENCE / Cognitive Science |2 bisacsh | |
| 650 | 7 | |a PSYCHOLOGY / Cognitive Psychology |2 bisacsh | |
| 650 | 7 | |a Cognition |2 fast | |
| 650 | 7 | |a Cognition / Age factors |2 fast | |
| 650 | 7 | |a Cognition / Effect of drugs on |2 fast | |
| 650 | 4 | |a Cognition | |
| 650 | 4 | |a Cognition |x Age factors | |
| 650 | 4 | |a Cognition |x Effect of drugs on | |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=187951 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028525423 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=187951 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=187951 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175511434297344 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043101231 |
| collection | ZDB-4-EBA |
| ctrlnum | (ZDB-4-EBA)ocn124095086 (OCoLC)124095086 (DE-599)BVBBV043101231 |
| dewey-full | 153 |
| dewey-hundreds | 100 - Philosophy & psychology |
| dewey-ones | 153 - Conscious mental processes & intelligence |
| dewey-raw | 153 |
| dewey-search | 153 |
| dewey-sort | 3153 |
| dewey-tens | 150 - Psychology |
| discipline | Psychologie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05507nmm a2200529zcb4500</leader><controlfield tag="001">BV043101231</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151126s2006 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1280810556</subfield><subfield code="9">1-280-81055-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1429467711</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-4294-6771-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781280810558</subfield><subfield code="9">978-1-280-81055-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781429467711</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-4294-6771-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-EBA)ocn124095086</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)124095086</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043101231</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">153</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Thinking about cognition: concepts, targets and therapeutics</subfield><subfield code="c">C.G. Kruse ... [et al.] (eds.)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam</subfield><subfield code="b">IOS Press</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (144 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Solvay Pharmaceuticals Conferences</subfield><subfield code="v">v. 5</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">International conference proceedings</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">100 Years after the discovery of Alzheimer's disease, neurological diseases and psychiatric disorders represent the largest and fastest growing unmet medical market with 2 billion affected people worldwide. Life expectancy of humans continues to increase, and the world population is aging. Advanced age may lead to deterioration of cognitive functions of the brain. There seems to be consensus that on the background of aging, several factors may render humans prone to dementia. Psychiatric and neurological isorders such as schizophrenia, bipolar disorder or Parkinson's disease may contribute to development of dementia. More people today are looking for help regarding their learning and memory capabilities. </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Although increasing knowledge on neuronal networks s transforming our view of the human brain and its function and we understand psychiatric and neurological diseases better today than ever before, novel therapies are needed to respond to the growing demand of patients for assistance with memory loss and earning impairment. In fact, it is expected that novel therapies aiming at the processing of amyloid, or at activation of glutamatergic or nicotinergic systems will demonstrate adequate efficacy in improving learning and memory disturbances. This publication stands as a comprehensive overview of the cellular and molecular mechanisms underlying the development of cognitive impairment. It integrates discoveries concerning dementia, such as mild cognitive impairment and Alzheimer's disease associated dementia vascular dementia, retardation syndromes, and psychiatric and neurological disorders related cognitive impairments. </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">This book will be useful to physicians, biologists, and those pursuing an interest or concerned with memory impairment. 100 Years after te discovery of Alzheimer's disease, neurological diseases and psychiatric disorders represent the largest and fastest growing unmet medical market with 2 billion affected people worldwide. Life expectancy of humans continues to increase, and the world poplation is aging. Advanced age may lead to deterioration of cognitive functions of the brain. There seems to be consensus that on the background of aging, several factors may render humans prone to dementia. Psychiatric and neurological disorders such as shizophrenia, bipolar disorder or Parkinson's disease may contribute to development of dementia. More people today are looking for help regarding their learning and memory capabilities. </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Although increasing knowledge on neuronal networks is transforming ourview of the human brain and its function and we understand psychiatric and neurological diseases better today than ever before, novel therapies are needed to respond to the growing demand of patients for assistance with memory loss and learning impairment In fact, it is expected that novel therapies aiming at the processing of amyloid, or at activation of glutamatergic or nicotinergic systems will demonstrate adequate efficacy in improving learning and memory disturbances. This publication stands as a comrehensive overview of the cellular and molecular mechanisms underlying the development of cognitive impairment. It integrates discoveries concerning dementia, such as mild cognitive impairment and Alzheimer's disease associated dementia, vascular dementia retardation syndromes, and psychiatric and neurological disorders related cognitive impairments. </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">This book will be useful to physicians, biologists, and those pursuing an interest or concerned with memory impairment</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SCIENCE / Cognitive Science</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PSYCHOLOGY / Cognitive Psychology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cognition</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cognition / Age factors</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cognition / Effect of drugs on</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cognition</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cognition</subfield><subfield code="x">Age factors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cognition</subfield><subfield code="x">Effect of drugs on</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=187951</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028525423</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=187951</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=187951</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043101231 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:17:27Z |
| institution | BVB |
| isbn | 1280810556 1429467711 9781280810558 9781429467711 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028525423 |
| oclc_num | 124095086 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 Online-Ressource (144 p.) |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | IOS Press |
| record_format | marc |
| series2 | Solvay Pharmaceuticals Conferences |
| spelling | Thinking about cognition: concepts, targets and therapeutics C.G. Kruse ... [et al.] (eds.) Amsterdam IOS Press 2006 1 Online-Ressource (144 p.) txt rdacontent c rdamedia cr rdacarrier Solvay Pharmaceuticals Conferences v. 5 International conference proceedings 100 Years after the discovery of Alzheimer's disease, neurological diseases and psychiatric disorders represent the largest and fastest growing unmet medical market with 2 billion affected people worldwide. Life expectancy of humans continues to increase, and the world population is aging. Advanced age may lead to deterioration of cognitive functions of the brain. There seems to be consensus that on the background of aging, several factors may render humans prone to dementia. Psychiatric and neurological isorders such as schizophrenia, bipolar disorder or Parkinson's disease may contribute to development of dementia. More people today are looking for help regarding their learning and memory capabilities. Although increasing knowledge on neuronal networks s transforming our view of the human brain and its function and we understand psychiatric and neurological diseases better today than ever before, novel therapies are needed to respond to the growing demand of patients for assistance with memory loss and earning impairment. In fact, it is expected that novel therapies aiming at the processing of amyloid, or at activation of glutamatergic or nicotinergic systems will demonstrate adequate efficacy in improving learning and memory disturbances. This publication stands as a comprehensive overview of the cellular and molecular mechanisms underlying the development of cognitive impairment. It integrates discoveries concerning dementia, such as mild cognitive impairment and Alzheimer's disease associated dementia vascular dementia, retardation syndromes, and psychiatric and neurological disorders related cognitive impairments. This book will be useful to physicians, biologists, and those pursuing an interest or concerned with memory impairment. 100 Years after te discovery of Alzheimer's disease, neurological diseases and psychiatric disorders represent the largest and fastest growing unmet medical market with 2 billion affected people worldwide. Life expectancy of humans continues to increase, and the world poplation is aging. Advanced age may lead to deterioration of cognitive functions of the brain. There seems to be consensus that on the background of aging, several factors may render humans prone to dementia. Psychiatric and neurological disorders such as shizophrenia, bipolar disorder or Parkinson's disease may contribute to development of dementia. More people today are looking for help regarding their learning and memory capabilities. Although increasing knowledge on neuronal networks is transforming ourview of the human brain and its function and we understand psychiatric and neurological diseases better today than ever before, novel therapies are needed to respond to the growing demand of patients for assistance with memory loss and learning impairment In fact, it is expected that novel therapies aiming at the processing of amyloid, or at activation of glutamatergic or nicotinergic systems will demonstrate adequate efficacy in improving learning and memory disturbances. This publication stands as a comrehensive overview of the cellular and molecular mechanisms underlying the development of cognitive impairment. It integrates discoveries concerning dementia, such as mild cognitive impairment and Alzheimer's disease associated dementia, vascular dementia retardation syndromes, and psychiatric and neurological disorders related cognitive impairments. This book will be useful to physicians, biologists, and those pursuing an interest or concerned with memory impairment SCIENCE / Cognitive Science bisacsh PSYCHOLOGY / Cognitive Psychology bisacsh Cognition fast Cognition / Age factors fast Cognition / Effect of drugs on fast Cognition Cognition Age factors Cognition Effect of drugs on http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=187951 Aggregator Volltext |
| spellingShingle | Thinking about cognition: concepts, targets and therapeutics SCIENCE / Cognitive Science bisacsh PSYCHOLOGY / Cognitive Psychology bisacsh Cognition fast Cognition / Age factors fast Cognition / Effect of drugs on fast Cognition Cognition Age factors Cognition Effect of drugs on |
| title | Thinking about cognition: concepts, targets and therapeutics |
| title_auth | Thinking about cognition: concepts, targets and therapeutics |
| title_exact_search | Thinking about cognition: concepts, targets and therapeutics |
| title_full | Thinking about cognition: concepts, targets and therapeutics C.G. Kruse ... [et al.] (eds.) |
| title_fullStr | Thinking about cognition: concepts, targets and therapeutics C.G. Kruse ... [et al.] (eds.) |
| title_full_unstemmed | Thinking about cognition: concepts, targets and therapeutics C.G. Kruse ... [et al.] (eds.) |
| title_short | Thinking about cognition: concepts, targets and therapeutics |
| title_sort | thinking about cognition concepts targets and therapeutics |
| topic | SCIENCE / Cognitive Science bisacsh PSYCHOLOGY / Cognitive Psychology bisacsh Cognition fast Cognition / Age factors fast Cognition / Effect of drugs on fast Cognition Cognition Age factors Cognition Effect of drugs on |
| topic_facet | SCIENCE / Cognitive Science PSYCHOLOGY / Cognitive Psychology Cognition Cognition / Age factors Cognition / Effect of drugs on Cognition Age factors Cognition Effect of drugs on |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=187951 |